Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE)

PHASE3TerminatedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

April 26, 2022

Study Completion Date

April 26, 2022

Conditions
Eosinophilic Esophagitis (EoE)
Interventions
DRUG

Budesonide oral suspension

BOS 10 mL twice daily.

Trial Locations (45)

11023

Long Island Gastrointestinal Research Group LLP, Great Neck

11102

Mount Sinai Hospital, Icahn School of Medicine, Astoria

20176

Emeritas Research Group, Lansdowne Town Center

24502

Blue Ridge Medical Research, Lynchburg

27514

University of North Carolina at Chapel Hill, Chapel Hill

28277

Clinical Research of Charlotte, Charlotte

29615

Greenville Hospital, Greenville

30342

Childrens Center For Digestive Healthcare, Atlanta

31201

Gastroenterology Associates of Central Georgia, Macon

32806

Arnold Palmer Hospital for Children, Orlando

34452

Nature Coast Clinical Research LLC, Inverness

35233

Children's Hospital, Birmingham

37212

Vanderbilt University Medical Center, Nashville

38138

Gastro One, Germantown

40202

Indiana University, Louisville

44060

Great Lakes Gastroenterology, Mentor

44195

Cleveland Clinic, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

45267

University of Cincinnati, Cincinnati

45440

Gastrointestinal and Liver Diseases Consultants PC, Dayton

47150

Gastroenterology of Southern Indiana, New Albany

52242

University of Iowa Hospitals and Clinics, Iowa City

55446

Minnesota Gastroenterology PA, Plymouth

60611

Northwestern University, Chicago

66606

Cotton O'Neil Clinical Research Center, Topeka

70006

Clinical Trials Management LLC, Metairie

70809

Gastroenterology Associates, LLC, Baton Rouge

72117

Arkansas Gastroenterology, North Little Rock

73112

Digestive Disease Specialists, Inc., Oklahoma City

77024

Houston Endoscopy and Research Center, Houston

80045

Colorado Children's Hospital, Aurora

80218

Rocky Mountain Pediatric Gastroenterology, Denver

80907

Asthma and Allergy Associates PC, Colorado Springs

83404

Grand Teton Research Group, Idaho Falls

84132

Primary Children's Hospital, University of Utah, Salt Lake City

84405

Advanced Research Institute, Ogden

85016

Phoenix Childrens Hospital, Phoenix

85712

Del Sol Research Management, Tucson

92123

Rady Children's Hospital San Diego, San Diego

06010

Connecticut Clinical Research Foundation, Bristol

06106

Connecticut Children's Medical Center, Hartford

Connecticut GI, Hartford

00211

Tufts Medical Center, Boston

02115

Boston Children's Hospital, Boston

02467

Brigham and Womens Hospital, Chestnut Hill

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Takeda Development Center Americas, Inc.

INDUSTRY

lead

Shire

INDUSTRY

NCT03245840 - Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Participants With Eosinophilic Esophagitis (EoE) | Biotech Hunter | Biotech Hunter